Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 6 | 0 | 2 | 2 | 0 |
Analyst Firms Making Recommendations1
- HC Wainwright & Co.
- JP Morgan
- Morgan Stanley
- Canaccord Genuity
- Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Y-mAbs Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/15/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 74.05% | HC Wainwright & Co. | Robert Burns | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 10.76% | JP Morgan | Tessa Romero | $8 → $7 | Maintains | Underweight | Get Alert |
| 08/14/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | -20.89% | Morgan Stanley | Michael Ulz | $7 → $5 | Maintains | Underweight | Get Alert |
| 08/14/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 74.05% | HC Wainwright & Co. | Robert Burns | → $11 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 248.1% | Canaccord Genuity | William Plovanic | $21 → $22 | Maintains | Buy | Get Alert |
| 12/15/2022 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | -5.06% | B of A Securities | Alec Stranahan | $5 → $6 | Maintains | Neutral | Get Alert |
| 04/01/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | -5.06% | B of A Securities | Alec Stranahan | → $6 | Maintains | Neutral | Get Alert |
| 05/07/2021 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 786.08% | B of A Securities | Geoff Meacham | → $56 | Upgrade | Neutral → Buy | Get Alert |
| 06/07/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 232.28% | Canaccord Genuity | William Plovanic | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 89.87% | B of A Securities | Alec Stranahan | $6 → $12 | Maintains | Neutral | Get Alert |
| 05/10/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 10.76% | Morgan Stanley | Michael Ulz | $4 → $7 | Maintains | Underweight | Get Alert |
| 05/10/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 105.7% | Wedbush | David Nierengarten | $5 → $13 | Upgrade | Neutral → Outperform | Get Alert |
| 05/09/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 232.28% | Canaccord Genuity | William Plovanic | $18 → $21 | Maintains | Buy | Get Alert |
| 04/04/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 74.05% | HC Wainwright & Co. | Robert Burns | $19 → $11 | Maintains | Buy | Get Alert |
| 04/03/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | — | Guggenheim | Etzer Darout | — | Downgrade | Buy → Neutral | Get Alert |
| 03/31/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 184.81% | Canaccord Genuity | William Maughan | $20 → $18 | Maintains | Buy | Get Alert |
| 01/30/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | 105.7% | BMO Capital | Etzer Darout | $12 → $13 | Maintains | Outperform | Get Alert |
| 01/27/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | — | Morgan Stanley | Michael Ulz | — | Downgrade | Equal-Weight → Underweight | Get Alert |
| 01/05/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $6.32 | — | Cowen & Co. | Joseph Thome | — | Downgrade | Outperform → Market Perform | Get Alert |
What is the target price for Y-mAbs Therapeutics (YMAB)?
The latest price target for Y-mAbs Therapeutics (NASDAQ: YMAB) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $11.00 expecting YMAB to rise to within 12 months (a possible 74.05% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Y-mAbs Therapeutics (YMAB)?
The latest analyst rating for Y-mAbs Therapeutics (NASDAQ: YMAB) was provided by HC Wainwright & Co., and Y-mAbs Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Y-mAbs Therapeutics (YMAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Y-mAbs Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Y-mAbs Therapeutics was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating Y-mAbs Therapeutics (YMAB) correct?
While ratings are subjective and will change, the latest Y-mAbs Therapeutics (YMAB) rating was a reiterated with a price target of $0.00 to $11.00. The current price Y-mAbs Therapeutics (YMAB) is trading at is $6.32, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.